Metabolic modulation to improve MSC expansion and therapeutic potential for articular cartilage repair.

ABSTRACT:

Background

Articular cartilage degeneration can result from injury, age, or arthritis, causing significant joint pain and disability without surgical intervention. Currently, the only FDA cell-based therapy for articular cartilage injury is Autologous Chondrocyte Implantation (ACI); however, this procedure is costly, time-intensive, and requires multiple treatments. Mesenchymal stromal cells (MSCs) are an attractive alternative autologous therapy due to their availability and ability to robustly differentiate into chondrocytes for transplantation with good safety profiles. However, treatment outcomes are variable due to donor-to-donor variability as well as intrapopulation heterogeneity and unstandardized MSC manufacturing protocols. Process improvements that reduce cell heterogene

SUBMITTER: Tee CA 

PROVIDER: S-EPMC11406821 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature